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Identification of a gene signature 
for discriminating metastatic 
from primary melanoma using a 
molecular interaction network 
approach
Rahul Metri1, Abhilash Mohan2, Jérémie Nsengimana3, Joanna Pozniak3, Carmen Molina-
Paris4, Julia Newton-Bishop3, David Bishop  3 & Nagasuma Chandra1,2
Understanding the biological factors that are characteristic of metastasis in melanoma remains a key 
approach to improving treatment. In this study, we seek to identify a gene signature of metastatic 
melanoma. We configured a new network-based computational pipeline, combined with a machine 
learning method, to mine publicly available transcriptomic data from melanoma patient samples. 
Our method is unbiased and scans a genome-wide protein-protein interaction network using a novel 
formulation for network scoring. Using this, we identify the most influential, differentially expressed 
nodes in metastatic as compared to primary melanoma. We evaluated the shortlisted genes by a 
machine learning method to rank them by their discriminatory capacities. From this, we identified a 
panel of 6 genes, ALDH1A1, HSP90AB1, KIT, KRT16, SPRR3 and TMEM45B whose expression values 
discriminated metastatic from primary melanoma (87% classification accuracy). In an independent 
transcriptomic data set derived from 703 primary melanomas, we showed that all six genes were 
significant in predicting melanoma specific survival (MSS) in a univariate analysis, which was also 
consistent with AJCC staging. Further, 3 of these genes, HSP90AB1, SPRR3 and KRT16 remained 
significant predictors of MSS in a joint analysis (HR = 2.3, P = 0.03) although, HSP90AB1 (HR = 1.9, 
P = 2 × 10−4) alone remained predictive after adjusting for clinical predictors.
Malignant melanoma, a cancer arising from the melanocytes is reported to have one of the largest rates of increase 
in incidence worldwide1,2. According to the World Health Organization, current statistics indicate that 132,000 
cases occur globally each year3. The majority of primary tumours are cured by local excision4 but the trend 
towards increased numbers of tumours in older males (age and male sex5 being risk factors for melanoma death) 
suggests that metastatic AJCC stage IV melanoma will continue to increase in incidence. Although the advent of 
targeted therapies, such as BRAF inhibitors and checkpoint therapies have for the first time produced a survival 
advantage, long term survival is still only seen in around 20% of patients6. Improvement is therefore necessary 
both in its detection and in its treatment. Computational methods are necessary for an unbiased comprehensive 
analysis so as to identify the characterizing genes of the metastatic phenotype.
Genome sequencing and analysis by The Cancer Genome Atlas (TCGA) has led to the identification of driver 
mutations in around 70% of tumours and a classification of patients into BRAF, NRAS, NF1 and tripleWT sub-
types7. In addition, other studies have identified a series of mutations or copy number changes8. These have 
provided insights into the underlying molecular mechanisms but have little prognostic or diagnostic significance. 
Many of the currently available markers (TYR, HMGA2, TRIB2, MITF and PMEL) depend on the differential 
expression of these markers in the diseased state9–13. Although there was previously little agreement between 
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transcriptomic studies in melanoma, we recently replicated signatures described by Jonsson’s group14,15 giving 
rise to the view that increasing study size, better platforms and bioinformatics may now lead to the identification 
of better biomarkers.
The most common analytical tools used for biomarker identification are clustering methods16, classification 
using a support vector machine17, decision trees and random forest classifiers18,19, artificial neural networks20 and 
simple differential expression based analysis13,21. These methods are typically data-driven and do not consider any 
biological information of the component genes as an input, but have an advantage of identifying distinguishing 
features even when no information is available about that feature. On the other hand, biological networks, con-
structed on the basis of the known functions and interactions of individual molecules, offer alternate approaches 
that are superior to blind learning approaches. Networks have the added advantage of combining condition spe-
cific transcriptome data and allow understanding of the functional role of the individual genes capable of dis-
criminating disease from healthy or between different disease stages22–24. Machine learning methods on the other 
hand are capable of providing a quantitative picture of the classification efficiencies of the individual genes25,26. 
They fail when the number of features is higher than the number of samples. To get the best of both approaches, 
we have combined the two and used network analysis which facilitates the usage of machine learning methods by 
reducing the number of features to be tested for classification efficiency and derive the final signature. This type 
of a combination approach has been suggested earlier to yield the best classification as compared to individual 
methods alone27. Initially, a genome-scale molecular interaction network was rendered condition-specific by 
integrating transcriptome data. Next, we mined the networks to identify a shortlist of key components that would 
define the state of tumour, progression stages and key points of perturbation. We then used a machine learning 
method to derive different signatures with an optimal length to discriminate primary and metastatic melanoma, 
respectively. We then went on to validate the signature genes based on Melanoma specific survival (MSS) analysis 
from an independent cohort.
Results and Discussion
Biomarker identification strategy. We configured a pipeline to identify RNA based biomarker candi-
dates distinguishing metastatic melanoma from primary melanoma in an unbiased fashion using well established 
methods at each step. As illustrated in Fig. 1, the pipeline (a) begins with the reconstruction of knowledge-based 
Figure 1. A schematic representation of the biomarker identification pipeline. The pipeline involves 5 major 
steps. Condition specific network: Construction of weighted network using protein-protein interaction network 
and gene expression data. Shortest Path analysis: Identification of all-vs.-all nodes shortest paths using Dijkstra’s 
algorithm. Response Paths: Paths with highest differential activity in diseased condition identified using string 
matching metric. Influence paths: Prioritizing paths based on influence on the network. Signature genes: 
Feature ranking of genes to obtain minimal set classifying conditions. The conditions considered for study: 
Normal Skin (NS), Primary Melanoma (PM) and Metastasis Melanoma (MM). Analysis results in numbers is 
shown in bottom section of the image
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protein-protein interaction networks. (b) These are then rendered condition-specific by weighing the network 
based on fitted signal intensity values resulting in three different networks for NS, PM and MM respectively, using 
methods previously established by us28,29. (c) The PM and MM networks were either compared with each other 
or compared with NS to generate disease response networks. For this, the highest activity paths were compared 
for a given pair of conditions and the top-ranked perturbed paths shortlisted for inclusion in further steps. The 
selected set of such paths in each comparison were found to be well connected with each other and hence form 
the corresponding response networks. (d) This is followed by identification of high-influence paths based on the 
paths impact on the network by constructing network communities using standard graph theory approaches. (e) 
Highest ranked influential paths and genes in them were then used as an input into a machine learning classifier 
that yields a final signature that discriminated metastatic from primary melanoma and predicts the risk of disease 
progression in primary melanoma.
Among the publicly available transcriptome repositories for cutaneous melanoma, we initially selected a tran-
scriptional profiling dataset that contained data for tissue samples of primary melanoma, metastatic melanoma 
along with adjacent normal skin10. We used this to identify biomarker signatures to distinguish between (a) 
metastatic and primary melanoma (b) metastatic melanoma and normal skin (c) primary melanoma and normal 
skin. The shortlist of possible biomarker candidates was obtained and evaluated for the performance of the signa-
tures on an independent dataset for the first phase of validation and used it for pruning the candidate set, thereby 
deriving an optimal signature. For the next phase of fully independent validation, we evaluated the performance 
of the optimized biomarker panel using a large dataset from the Leeds Melanoma30 cohort for which survival 
information was available.
Response networks capture disease stage-specific variations in an unbiased fashion. We uti-
lized a comprehensive master network of interactions between human proteins previously constructed in the 
laboratory28 (Methods). The master network comprises 13733 proteins (nodes) connected by 179403 interactions 
(edges) and includes both structural as well as functional interactions, belonging to several signaling, metabolic 
and regulatory processes, thus providing a global coverage of the human protein interactome. We rendered the 
master network condition-specific by weighting the individual nodes proportional to their respective fitted gene 
expression intensities from the transcriptomes of 46 and 12 samples of primary melanoma (PM) and metastatic 
melanoma (MM), respectively10. The dataset also contained 16 normal skin (NS) samples. A transcriptome 
comparison of MM vs. PM indicated 925 differentially expressed genes (DEGs, adjusted p-value ≤ 0.05, fold 
change ≥ 2). The same comparison for PM vs. NS is in the order of 2739 DEGs while that in MM vs. NS are 4262. 
A majority of DEGs (72% of MM vs. PM) were present in the initial network, indicating that the network has 
high coverage of the variations in melanoma and a similar trend was observed in other comparisons as well. From 
the three condition-specific networks reflecting conditions of NS, PM and MM, we obtained shortest paths by 
computing paths for all-vs.-all node pairs in each weighted network.
The paths abstracted as strings were compared (MM vs. PM, PM vs. NS, MM vs. NS), using a string similarity 
metric, that provided a measure of dissimilarity among the three conditions (see Methods). Highest scoring paths 
in each comparison reflect the set of highest perturbations in the network. We use the term ‘highest perturbations’ 
to describe the top ranked difference paths in the given pair of conditions (Supplementary Figure S1). A total of 
about 188 million paths were computed for each condition, of which about 19.5% paths of MM were unique to 
paths of PM. Similarly, 15% paths of PM and 21% paths of MM were unique when compared to NS. Higher the 
dissimilarity score, higher are the differential activities and hence the paths were sorted on this basis. We selected 
only the top ranked 0.001% of paths consisting of ~50% DEGs for further analysis amounting to 36952, 28338 and 
39558 paths in the three comparisons MM vs. PM, PM vs. NS and MM vs. NS, respectively. A stringent threshold 
of 0.001% was used to obtain a shortlist containing sufficient number of promising candidates for taking them 
further in the pipeline, while minimising chances of false-positives. In each case, although only a small fraction of 
paths was selected, we observed that these paths form a well-connected subnet. The fact that they are connected 
subnets strongly suggests that the perturbations are not random in nature and appear to be orchestrated as a 
system’s response to melanoma. Thus these paths of highest perturbations in a MM vs PM comparison defines 
the systems’ response to progression of disease from a primary melanoma to a metastatic form and referred to 
as response paths. Likewise, the paths for PM vs NS and MM vs NS represent the systems’ response for primary 
melanoma with respect to normal skin or metastatic melanoma versus normal skin respectively. The response 
paths can also be viewed as highest differences in ‘flows’ in the network, where a ‘flow’ implies a transfer of effect 
through the path containing differentially regulated genes. The paths, in addition to differentially expressed genes, 
contain bridging genes that may be constitutively expressed at high levels, and also hub nodes that serve as the 
main link to multiple flows. The response networks were constructed using the response paths and consisted of 
9975 (MM vs. PM), 8457 (PM vs. NS) and 8899 (MM vs. NS) nodes. The potential of such response networks to 
identify top perturbations and a common core in disease-specific networks has been explored previously28,29. A 
response network of PM vs. NS is shown in Fig. 2A. This exercise resulted in elimination of 49% of DEGs, result-
ing in a list of 472 DEGs between MM and PM for further processing. Similarly, in the other two comparisons 
56% (PM vs. NS) and 53% (MM vs. NS) of DEGs were eliminated. A point to note is that the protein-protein 
interactome is likely to be incomplete, since many interactions may not even be characterized in any system 
and it is therefore possible to miss some promising DEGs at this step. This however is not a major limitation in 
our study, as our goal is to identify biomarkers with high discriminative power rather than evaluate all possible 
markers.
Functional enrichment analysis of the response networks. To gain insights about the functional categories of the 
genes in the response networks (foreground set), a gene enrichment analysis was carried out against all human 
genes (background set). The predominant biological processes of each of the response networks are illustrated 
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in Fig. 2B (Supplementary Table S2). For the MM vs. PM set, several processes linked to metastasis such as the 
phospholipid metabolic process (P = 1.5 × 10−3), protein-lipid complex assembly (P = 2.1 × 10−2), regulation of 
inflammatory response (P = 5.1 × 10−3), negative regulation of protein kinase activity (P = 4.5 × 10−2) and reg-
ulation of innate immune response (P = 3.7 × 10−2) were enriched. On the other hand, the processes of melano-
cyte differentiation (P = 8.8 × 10−3), pigment cell differentiation (P = 5.2 × 10−3), pigmentation (P = 2.5 × 10−2), 
regulation of ligase activity (P = 5.08 × 10−4), and cell cycle phase (P = 1.9 × 10−10) are the most enriched pro-
cesses in the PM vs. NS set. Overall, the enrichment analysis indicated that the cell cycle, immune process and 
processes related to metastasis are prominent in metastatic melanoma, whereas the pigmentation processes was 
predominantly only in the case of PM but not in MM, as reported earlier by Raskin et al.10 Another GO process, 
the negative regulation of the canonical Wnt signaling pathway (P = 6.4 × 10−4) was also present in both PM vs. 
NS and MM vs. NS enrichment. In addition, the metastatic condition has a high enrichment of genes related to 
lipid synthesis (P = 2.1 × 10−2), consistent with the report of Baenke et al. for various cancers31. SPP1 (osteopon-
tin), a gene involved in melanoma invasion and tumour progression32 is increased by 8-fold in MM compared 
to PM and is present in MM vs. PM response paths. In an earlier work, we have reported that SPP1 differential 
expression increased hazard of death33. MITF, RAC1, PTEN and Jak-Stat pathway proteins (STAT1 and STAT3) 
are some of other proteins involved in invasive and metastatic behaviour of malignant melanoma that are part of 
top-response networks34.
Screening for High influence genes in the response networks. The genes in the response network 
were further prioritized based on the extent of influence they wielded in the whole network. The network commu-
nities are densely connected subnets of the whole network and are involved in performing similar or interrelated 
biological functions35,36. Functional perturbations to the nodes percolate effectively due to high connectedness 
within a community. Based on the network topology, we identified 41 communities in the master network. We 
tested if the nodes in each response network showed good coverage of the communities and observed that most 
communities (87%) were indeed well covered (Fig. 2C), and hence it was meaningful to use community-spanning 
to identify the most-influential nodes in the response networks. We then score the paths in each top-response 
paths based on the number of communities they span using two scoring schemes: (a) the paths consisting of 
nodes that belong to maximum communities - max-span paths (the top 1% of paths spanning the largest number 
Figure 2. (A) A network view of response paths identified using the Jaro-Winkler metric for the MM vs. PM 
comparison. (B) Functional enrichment of differentially regulated genes in top-response paths of MM vs. PM, 
MM vs. NS and PM vs. NS. (C) Percentage coverage of genes in 41 communities by genes of top-response paths 
from 3 comparisons. (D) A subnetwork of response paths of MM vs. PM prioritized based on influence score.
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of communities) and (b) the paths with nodes belonging to a single community - min-span paths (the top 1% of 
paths within a community). Max-span paths are enriched with differential genes across multi-function commu-
nities while min-span paths are enriched with genes that are most important within a community.
The next filter in the biomarker identification pipeline retains only the highly influential paths and eliminates 
the rest. For this, we computed an influence score (equation 1) for each node to capture the extent of its topological 
importance in the network and the gene expression variation in the given condition, and thus obtained a measure 
of a consolidated influence score (equation 2) for each path. Top 1% of max-span and min-span paths ranked based 
on consolidated influence score in each condition were selected and high-influence networks were built. 72 paths 
(271 edges, 259 nodes) make the high-influence network of MM vs. PM (Fig. 2D). Similarly, 56 paths (192 edges, 
194 nodes) for PM vs. NS and 78 paths (278 edges, 263 nodes) for MM vs. NS form the high-influence networks 
(Supplementary Figure S3 and Table S3). 25 DEGs from the high-influence network were identified as possible 
candidates to discriminate MM from PM. Similarly, 54 and 104 DEGs were identified for PM vs. NS and MM 
vs. NS, respectively. These form the first version of the signature panels in each case (Supplementary Table S4).
Optimization of the panel length and performance evaluation. The signature genes were derived 
based on median expression values which are oblivious to the heterogeneity of the disease. Given that high extents 
of heterogeneity are typically observed among patients with the same clinical presentations, it becomes necessary 
to use a panel of genes. The next question therefore is to identify how many and which genes should constitute 
the panel to achieve high discrimination in multiple datasets. Towards this, the relative importance of each gene, 
when treated as a feature was computed in the present dataset (GSE15605). The feature ranking and the receiver 
operating curves (ROC) from a random forest classifier are shown in Supplementary Figure S4. KRT16, a regula-
tor of innate immunity in the skin, significantly downregulated in MM was found to be the highest discriminator 
between MM and PM. ALDH1A1, IRX4, REST, WNT3A and SPRR3 were the other top ranked genes (full list of 
all condition comparisons in Supplementary Table S5). Further, we retained only those genes that showed con-
sistent differential expression in another independent transcriptome dataset of 14 PM, 40 MM and 4 NS samples 
(GSE7553).
We thus identified a final panel of 6 genes (ALDH1A1, HSP90AB1, KIT, SPRR3, TMEM45B and KRT16) which 
achieved a classification of 87% for MM vs. PM, a panel of 20 genes achieved a classification of 95% for PM vs. NS 
and 96% by a panel of 25 genes for MM vs. NS. Figure 3 provides a comprehensive illustration of how each gene 
fared in the two datasets based on gene expression values. In addition, we compared the gene-expression fold 
change patterns for each gene with the available protein expression levels in melanoma tissue (no stage-specific 
data was available) and normal skin (Fig. 3), which showed reasonable agreement for many genes. The protein 
abundances were obtained from the human protein atlas, which were based on antibody staining of the mel-
anoma tissue. The panel is intended as a RNA-signature and hence differential proteomic data is not directly 
relevant. However, understanding the trend in protein abundances can provide insights towards a mechanistic 
understanding of the role of the individual gene products, in disease progression and lend support for the selec-
tion of biomarkers. Of the 6 markers, ALDH1A1 (P = 4.3 × 10−7) and HSP90AB1 (P = 4 × 10−3) are upregulated 
in 75% and 83% of patients respectively, while the other 4 genes KIT (P = 2 × 10−3), SPRR3 (P = 3.2 × 10−6), 
TMEM45B (P = 4 × 10−3) and KRT16 (P = 3.2 × 10−6) are downregulated in around 80% patients. We compared 
the discriminatory power of our panel with that of a similar-sized panel identified without the use of networks, 
based on only machine learning approach (Supplementary information, Table S1 and Figure S2), which showed 
that the network based methods have a distinct advantage in identifying the best panel and also contains biolog-
ically meaningful genes.
Figure 4A shows the log2 intensity values of these 6 genes for each condition in GSE15605, GSE7553 and 
TCGA. Figure 4B is ratio of upregulated genes expression product (HSP90AB1 and ALDH1A1) to the down-
regulated genes expression product (KIT, KRT16, SPRR3 and TMEM45B) among the 6 gene signature for the 
3 cohorts and shows a good separation between the MM and PM. The combined effect size of the panel is seen 
to be very high in the first two datasets. A clear interpretation is difficult from the TCGA dataset, although the 
combined score is still higher in MM as compared to PM, because the dataset that is publicly accessible is a pool 
of samples of known primaries and metastatic samples of unknown primaries, and those collected from different 
tissues including from lymph nodes, but not individually annotated beyond the broad classification of ‘primary’ 
and ‘metastatic’ conditions’. The first two datasets on the other hand are more clearly annotated and the samples 
are all from the skin samples with known primaries.
Biological significance of the identified panel. To understand the significance of the identified genes, 
we first analysed how our signature fares with respect to expression of genes known to be differentially expressed 
in melanoma: tyrosinase (TYR), S100 family proteins, PMEL, MLANA, MITF, FN1, LDH, S100B, MIA and 
CSG437,38. From our analysis, we identified that 10 such genes are found either in our PM vs. NS or MM vs. NS 
signatures. We provide a full list of genes in Table 1, along with their functional categories and their role charac-
terised in melanoma or other cancers. 16 genes in our signatures such as QPRT, ALOX12 and PIP are seen to be 
either known or potential markers of other cancers, but not previously identified in melanoma.
Of the 6 gene MM vs. PM panel, HSP90 (heat shock protein 90) is a well-known marker for melanoma and its 
expression increases with disease progression39, ALDH1A1 is also a previously suggested marker and also poten-
tial target to decrease growth, tumorigenicity and metastasis of melanoma40. SPRR family and Keratin family 
genes were described to be downregulated in metastatic melanoma as compared to primary melanoma41, consist-
ent with the trend that we observe, for two members of the family, KRT16 and SPRR3. KIT, a downregulated gene 
in this set has been linked to disease progression and is also being explored as a therapeutic target42. Overall, as 
listed in Table 1, we observe that genes belonging to the following gene ontology categories are upregulated in the 
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PM vs. NS and MM vs. NS panels, (a) pigmentation, (b) cell differentiation, (c) cell proliferation and cell mobility 
(d) metabolic processes, while some genes related to (e) cell death and (f) skin development are downregulated.
Assessing disease severity and prognosis in a retrospective study of 703 primary melanoma 
samples from the Leeds melanoma Cohort. To validate the significance of the MM vs. PM signature, 
expressions of key genes from the identified network were analysed in the Leeds Melanoma cohort (703 primary 
tumours) to assess their individual and joint effect on melanoma-specific survival (MSS) as well as their associa-
tion with melanoma histological characteristics: AJCC stage, Breslow thickness, ulceration and mitotic rate (See 
Methods).
Melanoma specific survival analysis (MSS). In a univariable Cox model, elevated HSP90AB1 expression signif-
icantly predicted increased hazard of dying from melanoma (HR = 1.9, P = 0.0002) while higher expression of 
KRT16, KIT and TMEM45B reduced the death hazard (HR = 0.9 and P ≤ 0.05 for all three) (see Table 2). In unad-
justed multivariable analysis three genes showed independent effects: HSP90AB1, KRT16 and SPRR3 (Table 2). In 
multivariable analysis adjusted for sex, tumour site, age at diagnosis and AJCC stage, only HSP90AB1 remained 
significant with unchanged death hazard ratio estimate (HR = 2.0, P = 10−4, see Table 2).
Association with melanoma histology. The 4 genes that were associated with MSS in univariable analysis 
(Table 2) were also significantly correlated with ulceration, mitotic rate and Breslow thickness, and concordantly, 
AJCC stage (see Table 3). KIT, KRT16 and THEN45B are known to be expressed by normal skin appendages or 
stromal tissue, and hence it is possible that the differential expression of these genes in primary compared with 
metastatic tissue may represent sampling of those normal tissues in primary disease. Among these 4 genes, as 
Figure 3. Final signature genes for 3 condition comparisons. (A) 6 genes of MM vs. PM (B) 20 genes of PM vs. 
NS (C) 25 of MM vs. NS. The first two columns after gene name show the differential expression level in cohort 
GSE15605 and GSE7553, respectively. Third column show Venn diagrams indicating percentage of patients, 
the gene is differentially regulated in TCGA based on z-score. In the human protein atlas section, first four 
columns show the antibody stain levels observed in melanoma tissue. The size of each circle is based on a ratio 
of the number of patients showing particular expression to the total patients and the colouring is based on the 
intensity of expression. The last column is stain intensity in control tissue.
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expected, expression of HSP90AB1 increased with tumour thickness and higher mitotic rate, while the other 3 
were negatively correlated.
Composite gene expression score and MSS. A composite score was created using expressions of ALDH1A1, 
HSP90AB1, KIT, SPRR3, TMEM45B, KRT16 in the training dataset (random 2/3 of the total dataset, see 
Methods). When dichotomized on median and applied to the test data (remaining 1/3 of the data), higher values 
of score predicted worse prognosis with HR = 2.3, P = 0.003 (Fig. 5), remaining prognostic upon adjustment of 
sex, tumour site, age at diagnosis and AJCC stage with HR = 2.0, P = 0.01.
Composite gene expression score and tumour histology. The score was significantly lower in samples derived from 
patients with stage 1 (P = 5.4 × 10−14) but there was no difference between stages 2 and 3 (Fig. 6A). Tumours with 
the higher scores were more likely to be ulcerated (P = 1.7 × 10−12, Fig. 6B). Mitotic rate and Breslow thickness 
positively correlated with the score (see Fig. 6C and D).
The scores obtained by removing up to 3 genes (firstly ALDH1A1, then ALDH1A1 and KIT and lastly these 
two and TMEM45B) did not significantly change the MSS results (Supplementary Figure S5). All the scores were 
comparable to the initial score and remained significant after adjustment. The score utilizing the three genes 
(HSP90AB1, SPRR3 and KRT16) was shown to be as strong as the initial 6-gene score in terms of predicting MSS.
Because KRT16 is highly expressed in the epidermis and its expression may not be entirely from tumours in 
our data, we further eliminated it and recalculated a score combining only the 2 remaining genes (HSP90AB1, 
SPRR3). This new score remained associated with MSS in the test data (Supplementary Figure S5D).
Thus, from the survival analysis, HSP90AB1 expression significantly predicted reduced survival (HR = 1.9, 
P = 2 × 10−4 in multivariable analysis and the result remained significant after the adjustment of confounders 
(HR = 2, P = 10−4). Expression of this gene was associated with higher likelihood of ulceration (P = 9 × 10−4), 
higher AJCC stage (P = 0.03) and it was positively correlated with mitotic rate (R = 0.13) and Breslow thickness 
(R = 0.2), which is concordant with MSS results.
Higher fold change (downregulated) of KIT, KRT16 and TMEM45B predicted better prognosis in univariable 
analysis, however the result did not remain significant in multivariable analysis adjusting confounders (Table 2). 
The expression of those genes negatively correlated with ulceration, thickness, mitotic rate and ultimately AJCC 
Figure 4. (A) log2 intensity values of the 6 genes for each condition in GSE15605, GSE7553 and TCGA. (B) 
The combined score which is computed as a ratio of product of the signal intensity (log2) of upregulated genes 
(HSP90AB1 and ALDH1A1) to the product of the signal intensity (log2) downregulated genes (KIT, KRT16, 
SPRR3 and TMEM45B).
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Gene 
symbol Description
Association 
with cancer
GO biological process RemarksA B C
Genes in PM vs. NS
TYR* ↑ Tyrosinase ✓ pigmentation Well established biomarker of melanoma9
RGS20* ↑ Regulator Of G-Protein Signaling 20 ✓ cell differentiation Involved in cancer cell aggregation, migration, invasion and adhesion in other cancers51
PLA1A ↑ Phospholipase A1 Member A ✓ metabolic process Identified to be related to short survival of melanoma patients52.
SNCA ↑ Synuclein Alpha ✓ metabolic process Protein of many diseases and also reported as biomarker of malignant melanoma53.
QPRT ↑ Quinolinate Phosphoribosyltransferase ✓ metabolic process A potential marker for follicular thyroid carcinoma54.
MLANA ↑ Melan-A ✓ An established melanoma biomarker37
AP1S2* ↑ Adaptor Related Protein Complex 1 Sigma 2 Subunit ✓ ✓ intracellular protein transport
Upregulated in expression profile of 20 cancer 
types55
PLAT* ↑ Plasminogen Activator, Tissue Type ✓ cell mobility Plasminogen activation system studied in uveal melanoma56
MLPH ↑ Melanophilin ✓ intracellular protein transport Differentially expressed in melanoma
57
WIPI1 ↑ WD Repeat Domain, Phosphoinositide Interacting 1 ✓ metabolic process Coordinates Melanosome Formation and Melanogenic Gene Transcription58
ARPC1B* ↑ Actin Related Protein 2/3 Complex Subunit 1B ✓ ✓ cell mobility Prediction marker for choroidal malignant melanoma and lung cancer59
S100B ↑ S100 Calcium Binding Protein B ✓ cell proliferation An established melanoma biomarker37,60
TIMP1 ↑ TIMP Metallopeptidase Inhibitor 1 ✓ cell proliferation Timp1 interacts with CD63 to activate PI3-K signaling pathway in melanoma61,62
CD63 ↑ CD63 Molecule ✓ cell mobility
FYN* ↑ FYN Proto-Oncogene, Src Family Tyrosine Kinase ✓ ✓ cell mobility Potential biomarker for melanoma and other cancers63,64.
FN1* ↑ Fibronectin 1 ✓ cell mobility Used in a diagnostic assay of metastatic melanoma65
SFN* ↓ Stratifin ✓ ✓ cell death Downregulated in melanoma and other cancers12,66
ALOX12* ↓ Arachidonate 12-Lipoxygenase, 12S Type ✓ ✓ skin development Biomarker for prostate cancer and also downregulated in melanoma11,67
LGALS7 ↓ Galectin 7 ✓ ✓ apoptotic process Dual role observed in melanoma. Downregulation studied in cervical cancer and gastric cancer68–70
PIP* ↓ Prolactin Induced Protein ✓ regulation of immune system process Biomarker for Breast Cancer
71
Genes in MM vs. NS
SERPINE2 ↑ Serpin Family E Member 2 ✓ cell differentiation Therapeutic target for colorectal cancer52,72
S100A1 ↑ S100 Calcium Binding Protein A1 ✓ cell proliferation Established melanoma marker37
PHLDA1 ↑ Pleckstrin Homology Like Domain Family A Member 1 ✓ cell differentiation Expression involved in intestinal tumorigenesis73
TAF1A ↑ TATA Box-Binding Protein-Associated Factor 1A Regulation of transcription
UBE2C ↑ Ubiquitin Conjugating Enzyme E2 C ✓ cell proliferation Therapeutic target for melanoma74
LDHB ↑ Lactate Dehydrogenase B ✓ metabolic process Established biomarker of melanoma75
PARP1 ↑ Poly(ADP-Ribose) Polymerase 1 ✓ cell differentiation Associated with poor survival of melanoma patients76
ASPM ↑ Abnormal Spindle Microtubule Assembly ✓ cell differentiation Has a pro-invasion role in metastasis77
ALDH1A3 ↑ Aldehyde Dehydrogenase 1 Family Member A3 ✓ metabolic process Identified as marker and target of melanoma therapeutics78
PRKAR1A ↑ Protein Kinase A Type 1a Regulatory Subunit ✓ cell differentiation Overexpression studied in cholangiocarcinoma79
MCM3 ↑ Minichromosome Maintenance Complex Component 3 ✓ metabolic process Is a possible independent prognostic marker for melanoma80
AASS ↑ Aminoadipate-Semialdehyde Synthase ✓ metabolic process Is an oncogene81
SDCBP ↑ Syndecan Binding Protein ✓ cell mobility Involved in cancer development and progression82
COL4A6 ↓ Collagen Type IV Alpha6 Chain ✓ ✓ cell adhesion Involved in aggressiveness and metastasis of melanoma and other cancers83
AACS ↓ Acetoacetyl-CoA Synthetase ✓ cell differentiation Low expression studied in tumor tissues84
SGK2 ↓ SGK2,Serine/ThreonineKinase 2 ✓ regulation of cell growth Dowregulated in melanoma
85
Table 1. Biological significance of PM vs. NS and MM vs. NS signature. *Genes also present in MM vs. NS 
signature. A: Melanoma biomarker B: Studies related to melanoma C: Studies related to other cancers.
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stage, which is consistent with positive prognostic value. The lack of an independent effect of these genes on 
MSS is explained by this correlation with these other prognostic tumour characteristics. Although HSP90AB1 
correlated with these tumour characteristics as well (see Table 3), its residual effect on MSS remained significant, 
suggesting a putatively more potent role.
From the second approach, we see that the 6-gene score trained in 2/3 of the data was a strong predictor of 
MSS in the remaining 1/3, independent of AJCC stage; hence it might be explored as a prognostic biomarker. 
This independent prognostic effect was observed in spite of the 6-gene score being also associated with classical 
melanoma prognostic factors (AJCC stage, ulceration, mitotic rate and Breslow thickness). Interestingly, even 
after eliminating 3 of the 6 genes, the new 3-gene score (HSP90AB1, SPRR3, KRT16) remained strongly predictive 
of MSS. This suggests that 3 of the 6 genes identified in the protein network analysis may play a key role in mela-
noma progression. We note that the combined effect of the 3 genes is roughly similar to that of HSP90AB1 alone, 
which is consistent with the results from multivariable analysis which singled out this gene as the only significant 
when melanoma characteristics are adjusted (Table 2). Therefore, the results from our two analysis approaches 
highlight the importance of HSP90AB1 in progression of melanoma.
Conclusions
We developed a pipeline that combines a network approach with machine learning, through which we identified 
a biomarker signature capable of discriminating metastatic from primary melanoma tumours. The approach is 
based on constructing condition-specific genome-wide molecular interaction networks that are specific to each 
condition and subsequently mining the networks to identify nodes most influential in differentiating between dis-
ease stages. The signature genes identified by this network approach have been previously suggested as melanoma 
markers. In addition, our approach also identifies new potential markers. For many of these, there are studies 
reported in literature, supporting their roles in the pathophysiology. The discriminatory signature between MM 
and PM comprises a panel of 6 genes, which exhibit a 6 to 7 fold difference in their combined score between MM 
and PM. Melanoma specific survival (MSS) analysis for these 6 genes showed 3 genes HSP90AB1, SPRR3 and 
KRT16 to be strongly predictive of survival, of which HSP90AB1 by itself remained significant for predicting risk 
of disease progression, even after adjusting for confounding variables and hence has an added prognostic value. 
In addition to the 6-gene panel, our approach also identified two panels of 20 and 25 genes that can discriminate 
PM from NS and MM from NS, respectively.
Materials and Methods
Datasets. Microarray datasets (i) GSE15605, that contain expression profiles of 16 normal skin, 46 pri-
mary melanoma and 12 metastatic melanoma samples10, and (ii) GSE7553, that contains expression profiles of 
14 primary melanomas, 40 metastases, taken from tumor samples from patients and 4 normal skin samples as 
controls12, were obtained from the NCBI Gene Expression Omnibus (GEO) and used for the discovery phase. 
Additional datasets used for validation are: (iii) Transcriptomic data of 703 primary melanoma patients from the 
Leeds Melanoma Cohort generated from formalin fixed primaries using the Illumina DASL array (iv) TCGA 
dataset – 104 primary melanoma and 367 metastatic melanoma, as available through the cBio Cancer Genomics 
Portal43, and (v) The Human Protein Atlas44 containing measurements of proteins based on antibody staining 
from a few melanoma patients.
Gene
Univariable MSS Multivariable unadjusted MSS Multivariable adjusted MSS
HR P value HR P value HR P value
ALDH1A1 0.9 0.1 0.9 0.2 0.9 0.3
HSP90AB1 1.9 2 × 10−4 1.7 0.002 2.0 10−4
KIT 0.9 0.05 0.9 0.3 1.0 0.2
SPRR3 1.03 0.5 1.1 0.03 1.0 0.5
TMEM45B 0.9 0.005 0.96 0.4 1.0 0.5
KRT16 0.9 0.001 0.93 0.04 0.9 0.07
Table 2. Hazard ratios for MSS for individual genes in the whole dataset&. &Death hazard ratio (HR) reflects the 
change from the baseline of 1.0 each time the gene expression is doubled. 
Gene AJCC (Pvalue) Ulceration (Pvalue) Mitotic rate correlation (P-value) Breslow thickness correlation(P-value)
ALDH1A1 0.4 0.4 −0.04 (0.4) −0.01(0.7)
HSP90AB1 0.03 9 × 10−4 0.13 (0.001) 0.2 (1.6 × 10−5)
KIT 5 × 10−5 10−5 −0.11 (0.005) −0.2 (2.3 × 10−10)
SPRR3 0.7 0.6 −0.08 (0.06) −0.06 (0.1)
TMEM45B 5.5 × 10−13 2.2 × 10−11 −0.2 (7.9 × 10−8) −0.3 (3.1 × 10−16)
KRT16 4.8 × 10−12 2 × 10−5 −0.2 (3.1 × 10−7) −0.3, (1.3 × 10−20)
Table 3. Association between each gene and histological features of melanoma.
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Leeds-cohort: 2184 participants with primary melanoma were recruited to the Leeds Melanoma Cohort. As 
previously described, whole genome transcriptomes were generated from formalin fixed samples taken using a 
tissue microarray needle14. Normalization and analysis was carried out in Leeds as described previously.
Transcriptome analysis. The microarray analysis was carried out using Bioconductor-R (http://www.bio-
conductor.org/). The raw intensity values for each tissue sample were normalized using the method GCRMA 
in Bioconductor package affy. eBayes function was used to identify differential gene expression on linear fitted 
Figure 5. Survival curves according to the combined 6-gene score (unadjusted) in test data (1/3 of total 
sample). The score was dichotomised by the median.
Figure 6. The 6-gene score distribution by AJCC stage (A), ulceration status (B), mitotic rate (C) and Breslow 
thickness (D). Note the log scale for mitotic rate and Breslow thickness.
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model generated by lmFit from the package LIMMA. The P-values obtained were adjusted for multiple tests using 
Benjamini-Hochberg false discovery rate method. Genes with adjusted P-value ≤ 0.05 and a fold change of ±2 
were considered as differentially expressed genes (DEGs).
Protein-protein interaction network. A master human protein-protein interaction network curated ear-
lier in the laboratory28 was used. The master network, where proteins were considered as nodes and interactions 
as edges, consists of 17015 nodes and 200361 edges, of which nearly 80% were directed edges and the rest taken 
as bi-directional edges (Supplementary information). The available transcriptome data for melanoma GSE15605, 
mapped onto 21209 genes and finally the corresponding protein-protein interaction network of melanoma genes 
consisted of 13733 proteins and 179403 interactions.
Construction of condition-specific interaction networks. The network was rendered 
condition-specific by integrating it with the gene-expression profile of that condition. The nodes in the network 
were assigned weights based on the fitted normalized signal intensity values of all genes of NS, PM and MM con-
dition, thus obtaining three networks. The edge between two nodes was weighted as the inverse of the product of 
the node weights making it compliant with Dijkstra’s algorithm.
Identification of response paths for each comparison. Response paths are the paths that are highly 
perturbed between two conditions. Between all-vs-all nodes, high-activity paths were computed using Dijkstra’s 
algorithm implemented in python-igraph45, on condition-specific interaction network of both conditions. The 
high-activity paths between any two nodes (source and target) in a network were modelled as the linear combi-
nation of genes through which information flows with minimal resistance. A path between two nodes is termed 
‘perturbed’ if the nodes used to transmit information between the source and target was altered between the 
two conditions being compared. The paths were considered as strings and the path deregulation was captured 
using the Jaro-Winkler (JW) distance, a string matching metric46 (Supplementary File). The Jaro-Winkler score 
was normalized between 0 and 1 with 0 indicating an exact match. The top 0.001% perturbed (dissimilar) paths 
between two conditions were selected using this metric and considered further as response paths.
Functional enrichment analysis was carried out using web-based tool PANTHER – Protein Analysis Through 
Evolutionary Relationships. The P-values are FDR corrected using Bonferroni correction and considered signif-
icant if adjusted P-value < 0.0547.
Identification of high-influence paths. Identification of paths that have the highest influence in the net-
work involved two steps, the first to detect communities or clusters in the network and the second to compute the 
influence of paths based on the span of these paths across communities and influence wielded by each node in 
these paths on the entire network.
Community detection for the network. Communities were computed using an unweighted, master PPI network 
to identify the span of paths and reduce the total number of paths based on their efficiency to percolate effect of 
differential expression. For detecting communities, the Fast-greedy algorithm48 implemented in igraph45 was used 
as it is proven to reflect biological network properties efficiently over other community detection methods49. A 
minimal node size ≥4 was imposed to consider a community, which yielded 41 communities, which were taken 
through further steps in the pipeline.
Max-span and Min-span high influence paths. The response paths overlapping on maximum communities were 
classified as max-span paths, which reflect high inter-community influence and the response paths assigned to 
a single community were classified as min-span paths and reflect high intra-community influence. Further, an 
influence score was computed for each node in the max-span and min-span paths. The score is a combination of 
the differential expression of the node and its topological position in the network. The influence score of node v 
is given as:
= ×
+ +Influence score Fold change DC E BC
3 (1)v v
v v v
Where,
DC (Degree conserved), E (eccentricity) and BC (betweeness centrality) values were computed using func-
tions in python-igraph (See supplementary file).
Consolidated Influence score. After obtaining an influence score of each node in the max-span and min-span 
paths, a consolidated influence score was computed for each path.
= ∑ =Consolidated Influence score Influence score
n (2)p
i
n
i1
Where, n = number of nodes in path P.
It is the sum of influence scores of all nodes in the path, normalized by the path length. The max-span paths 
and min-span paths with high score were finally shortlisted to generate a high-influence network for each condi-
tion. The DEGs from these high influence networks were further validated for their ability to classify the condi-
tions in a larger dataset.
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Identifying discriminatory genes. From the set of high influence nodes, those that are the most discrim-
inatory between the two conditions in a comparison are then identified. This module involves two steps, the first 
determines the feature importance and the second prunes the list to finally identify a signature with the best 
classifying power and the least length.
Feature Importance. The ‘extra trees’ classifier was employed to rank important features. The number of esti-
mates was set to 500 while the class weights were automatically assigned so that proportional weights were given 
to undersampled/oversampled class labels. The criteria for selection was based on entropy (i.e. information gain) 
and the maximum number of features selected for finding the best split was taken as the sqrt of n_features. The 
maximum depth was disabled and the nodes were expanded until all leaves are pure.
Classification accuracy of the final signature. An AdaBoost classifier wrapper was used around the 
random forest algorithm to compute the classification accuracy of the signature gene set. The number of estima-
tors was set to 500 with a learning rate of 0.08 and the criterion for selection was based on entropy. The boosting 
function is implemented using the Stagewise Additive Modeling with a Multiclass Exponential loss function 
(SAMME)50. A stratified K-fold was used for cross validation (see supplementary file).
Validation in the Leeds Melanoma Cohort. Three types of analysis were performed in transcriptomic 
data in the Leeds Melanoma Cohort using the top ranked network genes:
 1) Univariable and multivariable association with melanoma-specific survival (MSS) in a Cox proportional 
hazards regression, adjusted and unadjusted for patient age at diagnosis, gender, AJCC stage and tumour 
site.
 2) Univariable association of each gene with melanoma histological features using the Kruskall-Wallis test for 
the categorical variables (AJCC stage, ulceration) and the Spearman correlation coefficient for continuous 
variables (Breslow thickness and mitotic rate).
 3) A composite gene expression score was created by calculating a weighted sum of the expression of each 
gene. The weight was the univariable log hazard-ratio from MSS analysis in a random selection of 2/3 of 
the dataset (training set). This score was then applied to the remaining 1/3 (test set) to assess its prediction 
of MSS and association with tumour histology (AJCC, ulceration, Breslow thickness and mitotic rate). The 
score’s stability was assessed by removing one by one the genes that had earlier shown the smallest inde-
pendent effect on MSS in multivariable analyses.
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